A systematic review and meta-analysis in overweight/obese patients with/without diabetes mellitus reported that GLP-1 receptor agonists were superior to SGLT-2 inhibitors for HbA1c (MD: -0.39%, 95% CI (-0.70 to -0.08)) and weight reduction (MD: -11.51 kg, 95% CI (-12.83 to -10.21)) [115]. This evidence concerns the gene GLP1R and diabetes mellitus.